Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients

Xue-Han Mao, MD, Yan Xu, MD, Yuting Yan, Junling Zhuang, MD PhD, Huishou Fan, Weiwei Sui, Jiahui Liu, Shuhui Deng, MD, Shuhua Yi, MD, Lugui Qiu, MD, Gang An

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-140225

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Ryu Lv, Yi Wang, Tingyu Wang, Xiong Wenjie, Huijun Wang, Yuting Yan, Qi Wang, Wei Liu, Gang An, MD PhD, Wenyang Huang, Weiwei Sui, MD, Yan Xu, MD, Zhen Yu, MD, Dehui Zou, MD, Jianxiang Wang, MD, Lugui Qiu, MD, Shuhua Yi, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138592

Published: 2020

Journal Articles

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Xue-Han Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Chenxing Du, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140464

Published: 2020

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Yan Xu, MD, Yao Yao, Woojun Daniel Park, Sanika Derebail, MS, Chandraditya Chakraborty, PhD, Shidai Mu, Rafael Alonso Fernández, Srikanth Talluri, PhD, Zuzana Chyra, PhD, Kenneth Wen, Qingsheng Yan, Osasenaga Idahor, Selene Cipri, Rao Prabhala, Kenneth Anderson, MD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-143327

Published: 2020

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Zuzana Chyra, PhD, Mehmet Kemal Samur, PhD, Anil Aktas-Samur, PhD, Yan Xu, MD, Eugenio Morelli, MD, Sophia Adamia, PhD, Woojun D Park, Lin Charles, PhD, Masood A. Shammas, PhD, Roman Hajek, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-142587

Published: 2020

Journal Articles

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Chandraditya Chakraborty, PhD, Eugenio Morelli, MD, Srikanth Talluri, PhD, Sanika Derebail, MS, Yan Xu, MD, Yao Yao, María Linares, Alba Rodríguez García, Kenneth Anderson, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-142178

Published: 2020

Journal Articles

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2019) 134 (Supplement_1): 579.

https://doi.org/10.1182/blood-2019-124953

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Xuehan Mao, MD, Yan Xu, MD, Yuting Yan, Jiahui Liu, Huishou Fan, Weiwei Sui, Shuhui Deng, MD, Zengjun Li, Lugui Qiu, MD PhD, Gang An

Blood (2019) 134 (Supplement_1): 4363.

https://doi.org/10.1182/blood-2019-125044

Published: 2019

Journal Articles

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

Yan Xu, MD, Matthew Ho, PhD, Mehmet Kemal Samur, PhD, Kenneth Wen, Shuhui Deng, MD, Lanting Liu, MD, Tengteng Yu, MD PhD, Zuzana Chyra, PhD, Sanika Derebail, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 5539.

https://doi.org/10.1182/blood-2019-130902

Published: 2019

Journal Articles

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Blood (2018) 132 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2018-99-118994

Published: 2018

Journal Articles

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Tommaso Perini, MD, Raphael Szalat, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Matthew Lawlor, Christopher J. Ott, PhD, Na Li, MD, Yan Xu, MD, Kenneth Wen, BS, Nicola Amodio, PhD, Eugenio Morelli, MD, Kenneth Anderson, MD, Fabio Ciceri, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 60.

https://doi.org/10.1182/blood-2018-99-118401

Published: 2018

Journal Articles

Evaluation of Definitions for Oral Anticoagulant–Associated Major Bleeding: A Population-Based Cohort Study

Yan Xu, MD, Tara Gomes, PhD MHSc, Philip S. Wells, MDMSc,FRCP, Ana Johnson, PhD, Michelle Sholzberg, MD

Blood (2018) 132 (Supplement 1): 426.

https://doi.org/10.1182/blood-2018-99-111207

Published: 2018

NARROW

Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Development of a Clinical Risk Stratification for Patients with Newly Diagnosed Multiple Myeloma

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Evaluation of Definitions for Oral Anticoagulant–Associated Major Bleeding: A Population-Based Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only